Literature DB >> 33778085

Islet Transplantation Reverses Podocyte Injury in Diabetic Nephropathy or Induced by High Glucose via Inhibiting RhoA/ROCK/NF-κB Signaling Pathway.

Chongchu Huang1, Yi Zhou1, Hongjian Huang1, Yushu Zheng1, Lijun Kong1, Hewei Zhang1, Yan Zhang2, Hongwei Wang1, Mei Yang3, Xiaona Xu4, Bicheng Chen1.   

Abstract

OBJECTIVE: Abnormal signaling pathways play a crucial role in the mechanisms of podocyte injury in diabetic nephropathy. They also affect the recovery of podocytes after islet transplantation (IT). However, the specific signaling abnormalities that affect the therapeutic effect of IT on podocytes remains unclear. The purpose of this study was to assess whether the RhoA/ROCK/NF-κB signaling pathway is related to podocyte restoration after IT.
METHODS: A mouse model of diabetic nephropathy was established in vivo using streptozotocin. The mice were then subsequently reared for 4 weeks after islet transplantation to determine the effect of IT. Islet cells, CCG-1423 (RhoA Inhibitor), and fasudil (ROCK inhibitor) were then cocultured with podocytes in vitro to assess their protective effects on podocyte injury induced by high glucose (HG). Protein expression levels of RhoA, ROCK1, synaptopodin, IL-6, and MCP-1 in kidney tissues were then measured using immunohistochemistry and Western blotting techniques.
RESULTS: Islet transplantation reduced the expression levels of RhoA/ROCK1 and that of related inflammatory factors such as IL-6 and MCP-1 in the kidney podocytes of diabetic nephropathy. In the same line, islet cells reduced the expression of RhoA, ROCK1, and pp65 in immortalized podocytes under high glucose (35.0 mmol/L glucose) conditions.
CONCLUSIONS: Islet transplantation can reverse podocyte injury in diabetes nephropathy by inhibiting the RhoA/ROCK1 signaling pathway. Islet cells have a strong protective effect on podocytes treated with high glucose (35.0 mmol/L glucose). Discovery of signaling pathways affecting podocyte recovery is helpful for individualized efficacy evaluation and targeted therapy of islet transplantation patients.
Copyright © 2021 Chongchu Huang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33778085      PMCID: PMC7969114          DOI: 10.1155/2021/9570405

Source DB:  PubMed          Journal:  J Diabetes Res            Impact factor:   4.011


  30 in total

1.  Inflammation and pathogenesis of diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Metabolism       Date:  2004-02       Impact factor: 8.694

2.  Areal density measurement is a convenient method for the determination of porcine islet equivalents without counting and sizing individual islets.

Authors:  N Lembert; J Wesche; P Petersen; M Doser; H D Becker; H P T Ammon
Journal:  Cell Transplant       Date:  2003       Impact factor: 4.064

3.  AOPPs induce MCP-1 expression by increasing ROS-mediated activation of the NF-κB pathway in rat mesangial cells: inhibition by sesquiterpene lactones.

Authors:  Jian-Cheng Wang; Yan Zhao; Si-Jia Chen; Jing Long; Qian-Qian Jia; Jia-Dai Zhai; Quan Zhang; Yue Chen; Hai-Bo Long
Journal:  Cell Physiol Biochem       Date:  2013-12-20

4.  Role of podocyte B7-1 in diabetic nephropathy.

Authors:  Paolo Fiorina; Andrea Vergani; Roberto Bassi; Monika A Niewczas; Mehmet M Altintas; Marcus G Pezzolesi; Francesca D'Addio; Melissa Chin; Sara Tezza; Moufida Ben Nasr; Deborah Mattinzoli; Masami Ikehata; Domenico Corradi; Valerie Schumacher; Lisa Buvall; Chih-Chuan Yu; Jer-Ming Chang; Stefano La Rosa; Giovanna Finzi; Anna Solini; Flavio Vincenti; Maria Pia Rastaldi; Jochen Reiser; Andrzej S Krolewski; Peter H Mundel; Mohamed H Sayegh
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

5.  A role for podocytes to counteract capillary wall distension.

Authors:  W Kriz; E Hackenthal; R Nobiling; T Sakai; M Elger; B Hähnel
Journal:  Kidney Int       Date:  1994-02       Impact factor: 10.612

Review 6.  Podocyte biology in diabetic nephropathy.

Authors:  J J Li; S J Kwak; D S Jung; J-J Kim; T-H Yoo; D-R Ryu; S H Han; H Y Choi; J E Lee; S J Moon; D K Kim; D S Han; S-W Kang
Journal:  Kidney Int Suppl       Date:  2007-08       Impact factor: 10.545

7.  Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.

Authors:  Vasantha Kolavennu; Lixia Zeng; Hui Peng; Yin Wang; Farhad R Danesh
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461

8.  Mechanisms of glomerular albumin filtration and tubular reabsorption.

Authors:  Akihiro Tojo; Satoshi Kinugasa
Journal:  Int J Nephrol       Date:  2012-05-20

Review 9.  Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis.

Authors:  Jae Seok Kim; Byoung Geun Han; Seung Ok Choi; Seung-Kuy Cha
Journal:  Biomed Res Int       Date:  2016-03-21       Impact factor: 3.411

10.  Fyn Mediates High Glucose-Induced Actin Cytoskeleton Reorganization of Podocytes via Promoting ROCK Activation In Vitro.

Authors:  Zhimei Lv; Mengsi Hu; Xiaoxu Ren; Minghua Fan; Junhui Zhen; Liqun Chen; Jiangong Lin; Nannan Ding; Qun Wang; Rong Wang
Journal:  J Diabetes Res       Date:  2016-01-06       Impact factor: 4.011

View more
  3 in total

Review 1.  Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell.

Authors:  Anjaneyulu Kowluru; Noah F Gleason
Journal:  Biochem Pharmacol       Date:  2021-12-28       Impact factor: 5.858

2.  Circ_0000064 promotes high glucose-induced renal tubular epithelial cells injury to facilitate diabetic nephropathy progression through miR-532-3p/ROCK1 axis.

Authors:  Huanlan Wang; Shenghua Huang; Taotao Hu; Shizhi Fei; Huanqiao Zhang
Journal:  BMC Endocr Disord       Date:  2022-03-15       Impact factor: 2.763

Review 3.  Caveolin-1 Regulates Cellular Metabolism: A Potential Therapeutic Target in Kidney Disease.

Authors:  Shilu Luo; Ming Yang; Hao Zhao; Yachun Han; Na Jiang; Jinfei Yang; Wei Chen; Chenrui Li; Yan Liu; Chanyue Zhao; Lin Sun
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.